Aktuellt
SENASTE
Redeye leaves a comment following Alzinova’s announcement of final study results from the phase Ib study with its vaccine candidate ALZ-101. We are encouraged to learn that the final results reinstate the positive data from the previous topline results, suggesting that ALZ-101 is well-tolerated and safe, elicits a high immune response in patients and shows indications of efficacy on cognitive and functional parameters.
LÄS MER
